Search Medical Condition
Please enter condition
Please choose location from dropdown
 

Medicine & Geriatrics, Hong Kong Clinical Trials

A listing of Medicine & Geriatrics, Hong Kong clinical trials actively recruiting patients volunteers.

RESULTS

Found (2369) clinical trials

A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) (Morpheus-Gastric Cancer)

A Phase Ib/II, open label, multi-center, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in patients with locally advanced unresectable or metastatic G/GEJ cancer (hereafter referred to as gastric cancer). Two cohorts will be enrolled in parallel in this study: the ...

Phase

0.5 miles

Learn More »

Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia

OBJECTIVES: Primary - Determine the maximum-tolerated dose (MTD) and recommended phase II dose of sorafenib in pediatric patients with relapsed or refractory solid tumors. - Determine whether pediatric patients with relapsed or refractory leukemia can tolerate the MTD of sorafenib for solid tumors. - Determine the tolerability, active N-oxide metabolite, ...

Phase

0.5 miles

Learn More »

Laboratory-Treated Peripheral Blood Cell Infusion After Donor Stem Cell Transplant in Treating Patients With Hematologic Cancers or Other Diseases

OBJECTIVES: Primary - Establish the feasibility of delayed infusion of ex vivo anergized donor peripheral blood mononuclear cells (PBMC) after CD34-selected megadose haploidentical hematopoietic stem cell transplantation (HSCT) in patients with hematopoietic cancers or other diseases. - Determine the feasibility of collecting parental allogeneic stimulator cells to induce anergy to ...

Phase

0.5 miles

Learn More »

Safety and Efficacy Study of TNX-650 to Treat Refractory Hodgkin's Lymphoma

Hodgkin's lymphoma (HL) is a lymphoid malignancy that accounts for approximately 7,000 to 8,000 new cancer cases per year in the United Sates. It occurs with a bimodal age-incidence distribution peaking in the 15- to 30-year old and 50- to 60-year old age groups. The pathological hallmark of the disease ...

Phase

0.5 miles

Learn More »

Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia

OBJECTIVES: Primary - To compare an early intensification regimen comprising two "acute myeloid leukemia" induction therapy blocks with a standard protocol IB regimen administered directly after induction therapy in medium-risk (MR) and high-risk (HR) patients with newly diagnosed acute lymphoblastic or biphenotypic leukemia. Secondary - To compare through a randomized ...

Phase N/A

0.5 miles

Learn More »

Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients

The main objective of this study is to learn which sapacitabine treatment is more likely to keep the cancer in check for at least one year in AML patients who are at least 70 years of age or older and in MDS patients who are at least 60 years of ...

Phase

0.5 miles

Learn More »

Cyclophosphamide Alemtuzumab Total-Body Irradiation and Donor Stem Cell Transplant in Treating Patients With Severe Aplastic Anemia

OBJECTIVES: - To assess the safety of the conditioning regimen using cyclophosphamide, total-body irradiation, and alemtuzumab in patients with severe aplastic anemia. - To assess engraftment and the risk of graft failure in this patient population. - To assess the risk of acute and chronic graft-vs-host disease. - To estimate ...

Phase

0.5 miles

Learn More »

Etoposide and Cisplatin in Treating Young Patients With Previously Untreated High-Risk Neuroblastoma Undergoing High-Dose Chemotherapy Stem Cell Transplant and Isotretinoin

OBJECTIVES: Primary - Estimate the response rate associated with two courses of cisplatin and protracted oral etoposide when administered as up-front window therapy to pediatric patients with previously untreated high-risk neuroblastoma undergoing high-dose chemotherapy and stem cell rescue followed by maintenance therapy comprising isotretinoin. - Describe the toxicities associated with ...

Phase

0.5 miles

Learn More »

Anti-CD45 Monoclonal Antibody Cytarabine Cyclophosphamide and Total-Body Irradiation With or Without Alemtuzumab in Treating Patients Undergoing a Donor Stem Cell Transplant For Advanced Leukemia or Other Hematologic Cancer

OBJECTIVES: Primary - To evaluate the toxicity and the anti-tumor activity of anti-CD45 monoclonal antibody in patients with relapsed or resistant leukemia or other hematologic malignancy undergoing allogeneic stem cell transplantation. Secondary - To describe the effects of anti-CD45 on normal hematopoiesis and on complement levels. - To describe the ...

Phase

0.5 miles

Learn More »

T-Lymphocytes in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

OBJECTIVES: Primary - To evaluate the safety of autologous T-lymphocytes genetically modified to express artificial T-cell receptors (CAR) targeting the CD19 molecule (CD19CAR) in patients with refractory or relapsed low-grade B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia. Secondary - To measure the survival and function of CD19CAR T-cells in vivo. ...

Phase

0.5 miles

Learn More »